Back to Sectors

SGHT

Sight Sciences, Inc.
7 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Signal Magnitude Chart

BEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 70% | 5/6/2026 | margin expansionBULLISH | 90% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | debt restructureMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%
bearishMay 6

Company continues to report significant net losses and negative operating cash flow.

earnings miss
60%
bullishMay 6

Maintained high gross margins of 86.2% with improvements in both reportable segments.

margin expansion
70%
bullishMay 6

Secured a final court judgment for $55.4 million in damages and ongoing royalties against Alcon.

regulatory action
90%
neutralMay 6

Amended Hercules Loan Agreement to extend interest-only period to February 2027.

debt restructure
40%

Filing History

10-QMay 6, 2026

The Q1 2026 filing reveals a company at a crossroads, balancing impressive commercial acceleration in dry eye treatment against a persistent burn rate. The 12.5% revenue growth and the successful navigation of the Alcon legal battle provide a strong bullish signal, suggesting that the company's intellectual property and market access strategies are working. However, the underlying financial instability—characterized by high-interest debt and a shrinking cash pile—serves as a critical counterweight. Investors are now weighing the certainty of the Alcon royalties and the scalability of the TearCare system against the risk of pipeline stagnation due to R&D cuts. The overall impact of the filing is a transition from a pure-play R&D firm to a commercial-stage entity that must now prove it can achieve positive cash flow without further diluting shareholders or incurring additional high-cost debt.